Abbott Laboratories (NYSE:ABT) – Abbott Announces FDA Approval of Its Supera® Stent to Treat People with Peripheral Artery Disease

[PR Newswire] – ABBOTT PARK, Ill., March 28, 2014 /PRNewswire/ — Abbott today announced that its Supera® Peripheral Stent System has received U.S. Food and Drug Administration (FDA) approval to treat people with . . . → Read More: Abbott Laboratories (NYSE:ABT) – Abbott Announces FDA Approval of Its Supera® Stent to Treat People with Peripheral Artery Disease Similar Articles: Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J, Pharmacyclics drug gets U.S. approval for leukemia Company Update – Abbott Laboratories (NYSE:ABT) – Abbott Laboratories Raised Its Dividend 57%, But Is It A Buy Right Now? Stock Update: Visa Inc. (NYSE:V) – Visa Inc. announces nomination of Alfred F. Kelly, Jr. and Maynard G. Webb, Jr. for election to the Board of Directors; Gary P. Coughlan announces decision not to stand for re-election in January